Similarly, Bcl-2 reduction has been achieved by packing EVs with therapeutic biomolecules such as silencing RNA (bcl-2 siRNA) and antisense oligonucleotides (ASOs), or by stripping EVs of cancer-causing circular RNA (circRNA) [47,48,49]. Here, BCL2 is linked to cancer.